Evolent Health Q2 Earnings Review: Debt Is Distressing, But Business Is Booming

Evolent Health, Inc. is awarded a contrarian Buy rating despite extreme indebtedness and recent net losses. EVH trades at a deeply distressed valuation (~0.2x forward sales) due to ~$967m long-term debt and persistent GAAP losses. Management projects >25% revenue growth and adjusted EBITDA ≥$150m in 2027, aiming to improve leverage and capital structure.

Seeking Alpha • Aug 13, 2026

Evolent Health Q2 Earnings Call Highlights

Evolent Health NYSE: EVH reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially, as the company benefited from the May launch of its Highmark partnership and continued growth in its Performance Suite business.

MarketBeat • Aug 8, 2026

Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript

Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

Evolent Announces Second Quarter 2026 Results

WASHINGTON, Aug. 6, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2026. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "We believe our results for the second quarter of 2026, our updated 2026 guidance and our 2027 outlook all demonstrate that Evolent is delivering strong growth, profitability and cash flow.

PRNewsWire • Aug 6, 2026

Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Aug 6, 2026

Evolent Health (EVH) Tops Q2 Earnings and Revenue Estimates

Evolent Health (EVH) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.1 per share a year ago.

Zacks Investment Research • Aug 6, 2026

Forget Nvidia. These 5 S&P 500 stocks are quietly going all in on AI.

The “Mag Seven” has become the “Bag Seven.” Sharp tech investors are looking elsewhere.

Market Watch • Jul 20, 2026

Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now

Healthcare IT is emerging as AI's next growth story as providers adopt AI to cut costs & improve care. Here we present three stocks that are likely to benefit.

Zacks Investment Research • Jul 16, 2026

Evolent To Release Second Quarter 2026 Financial Results on Thursday, August 6, 2026

WASHINGTON, July 8, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, before market open, with a conference call to follow at 8 a.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.

PRNewsWire • Jul 8, 2026

Should You Buy Evolent Health (EVH) After Golden Cross?

Evolent Health, Inc (EVH) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, EVH's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Zacks Investment Research • Jul 3, 2026